Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
758 6 |
Ultima descărcare din IBN: 2020-06-30 23:42 |
Căutarea după subiecte similare conform CZU |
616.132.2-089-085:615.3 (1) |
Patologia sistemului circulator, a vaselor sanguine. Tulburări cardiovasculare (975) |
Medicamentele potrivit originii lor (478) |
SM ISO690:2012 SIMIONOV, Lilia. Evaluarea efectelor tratamentului cu nebivolol asupra parametrilor disfuncţiei endoteliale și stresului oxidativ după angioplastia coronariană. In: Sănătate Publică, Economie şi Management în Medicină , 2016, nr. 5(69), pp. 26-30. ISSN 1729-8687. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Sănătate Publică, Economie şi Management în Medicină | ||||||
Numărul 5(69) / 2016 / ISSN 1729-8687 /ISSNe 2587-3873 | ||||||
|
||||||
CZU: 616.132.2-089-085:615.3 | ||||||
Pag. 26-30 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Currently, percutaneous transluminal coronary angioplasty (PCI) is an effective treatment for ischemic heart disease, but has a traumatic impact due to mechanical injury of the vascular endothelium. Postangioplasty vascular injury is followed by degradation and decrease of the bioavailability of nitric oxide (NO). Tangential to the endothelial dysfunction, oxidative stress is increasing its activity. The aim of the study was to evaluate the effects of treatment with nebivolol on the serum level of biomarkers – nitric oxide, superoxide dismutase (SOD) and malondialdehyde (MDA). The study included 42 patients with stable angina pectoris undergoing PCI who were administered 5 mg nebivolol associated with conventional care and dual antiplatelet therapy. Patients were evaluated preprocedural, postprocedural (24 hours) every 1, 3, 6, 12 months after PCI. The interval of 3, 6, 12 months after PCI in patients treated with nebivolol has determined statistically significant values in NO serum level that excess the level of the same biomarker measured at the reference pattern. Serum concentration SOD is still growing during treatment with nebivolol. The serum level of MDA is belittling, registering statistically significant values at the stage of 3 months. The survey results reveal a new opportunity of nebivolol administration of patients with stable angina pectoris undergoing PCI, due to the vasodilators properties of the medicament and confirmed through the increase of the NO bioavailability and antioxidant effects validated by reducing the serum level of MDA and elevation of serum SOD activity |
||||||
Cuvinte-cheie endothelial dysfunction, nitric oxide, oxidative stress, percutaneous coronary intervention, nebivolol |
||||||
|